Study: New Anticlotting Drug Beats Warfarin
Eliquis More Effective at Preventing Strokes in Patients With Atrial Fibrillation
Pros and Cons of New Drugs continued...
Brindis and Bohm agree that the newer agents will probably prove most useful for patients being prescribed anticlotting drugs for the first time and those for whom warfarin dosing proves problematic.
"If warfarin has been working with no problems, and the patient isn't all upset about the blood work, there is no reason to switch," Brindis explains.
The Eliquis study, dubbed Aristotle, was funded by Bristol-Myers Squibb and Pfizer. Bristol-Myers said an application for approving Eliquis for AF will be filed with the FDA later this year.